InspireMD, Inc. (NSPR) Fair Value 2026

NSPR · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (47/100)

Quick Summary — As of 2026-08-28, InspireMD, Inc. (NSPR) trades at $0.85. QOC: 6.1/10. Value Trap Risk: 47/100 (WARN). 1/13 models active.

Key Facts

Ticker
NSPR
Price
$0.85
Quality Score
6.1/10
Value Trap Risk
47/100
Models Active
1/13
Last Updated
Strength: Dynamic NAV suggests +11.3% upside with 51% confidence
Risk: Value Trap score of 47 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give NSPR?

1 Intrinsic Value Models vs. Current Price ($0.85)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.95 +11.3%

All Models Active

All 1 models are displayed above.

What Is InspireMD, Inc. (NSPR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, InspireMD, Inc. is potentially undervalued at its current price of $0.85. Based on our 13-model framework, InspireMD, Inc.'s intrinsic value is estimated at a median fair value of $0.95 — representing +11.3% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About NSPR?

1 of 13 models are currently active for NSPR. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does NSPR Rank in Medical Devices?

Among 159 Medical Devices stocks, NSPR ranks #83 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

As a biopharma enterprise, InspireMD, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating NSPR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is NSPR a Value Trap?

CirclFi's Value Trap algorithm assigns NSPR a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for InspireMD, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, InspireMD, Inc.'s fundamental quality profile registers 6.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NSPR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NSPR's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy InspireMD, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

STIMNeuronetics, Inc.QOC 6.2OMOutset Medical, Inc.QOC 6.1OFIXOrthofix Medical Inc.QOC 6.2AVRAnteris Technologies Global Corp.QOC 6.1CVRXCVRx, Inc.QOC 6.2CBLLCeriBell, Inc.QOC 6.1MDAISpectral AI, Inc.QOC 5.1GMEDGlobus Medical, Inc.QOC 9.2IARTIntegra LifeSciences Holdings CorporationQOC 7.1IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: STIM · OM · OFIX · AVR · CVRX · CBLL · MDAI · GMED · IART · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to NSPR?

6 companies across all industries closest to NSPR’s Quality of Company score of 6.1/10.

AYTUAytu BioPharma, Inc.QOC 6.1IOVAIovance Biotherapeutics, Inc.QOC 6.1INCRInterCure Ltd.QOC 6.1TROXTronox Holdings plcQOC 6.1TXOTXO Partners, L.P.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AYTU · IOVA · INCR · TROX · TXO · NVDA

Where Does NSPR Sit in CirclFi's Medical Devices Rankings?

NSPR is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About InspireMD, Inc.’s Valuation?

What is InspireMD, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for InspireMD, Inc. (NSPR). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NSPR overvalued or undervalued right now?

At $0.85, 1 of 1 active models suggest NSPR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits InspireMD, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.1 mean for NSPR?

InspireMD, Inc.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NSPR?

CirclFi analyzes NSPR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is NSPR a value trap in 2026?

InspireMD, Inc.'s Value Trap score is 47/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns InspireMD, Inc. (NSPR) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/NSPR/ · Methodology
Primary sources for this NSPR valuation
  • Financial statements: InspireMD, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001433607) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NSPR as of ; valuations recomputed .